# INNOGEN

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/innogen

- Industry: Biotechnology
- Headquarters: Shanghai, China
- Website: www.innogenpharm.com
- Total disclosed funding: $155M
- Latest round: Series B (Jan 10, 2024)
- Investors on record: 18

## About

Based in Shanghai, China, and founded in 2014, Guangzhou Innogen Pharmaceutical Group Co., Ltd., trading as INNOGEN, is an international pharmaceutical manufacturing and R&D company. The long-acting human-sourced GLP-1 drug passed the CDE clinical approval in May 2018. In August 2025, Innogen Pharmaceutical Technology Co., Ltd raised HKD 682.9 million in an IPO, selling 36.56 million shares at HKD 18.68 per share on the Hong Kong Stock Exchange under the ticker symbol "2591".
The company's product Diabigone is long-acting hypoglycemic Supaglutide injection for type 2 diabetes. It is currently undergoing clinical trials. The company's other pipeline research projects are original drugs for type 1 and type 2 diabetes, obesity, and diabetic complications. In addition to recombinant protein biopharmaceuticals, chemical products are also included in nearly ten pipeline products. One of the small molecule compounds has completed a clinical phase 1 study.
The company generates revenue through the research and development of medicines for diabetes and other metabolic diseases.
The company plans to ongoing the planned commercialization of its core product and expansion of the Group's internal sales and marketing team.

## Funding rounds

- Series B, Jan 10, 2024, $35M — Guangzhou Industry Investment Holding Group
- Series B, Feb 15, 2023 — Hanfu Capital, Huajin Dadao Investment, Mingzhe Asset, Shanghai Nuolin Pharmaceutical Partnership (Limited Partnership)
- Series A, Dec 23, 2021, $120M — China Everbright, China International Capital Corporation, Cowin Capital, CASH Capital, China Growth Capital, Everest VC, DYEE Capital, V Star Capital, Lanting Capital, Pudong Capital, Youshan Capital, Hangzhou Xiaochi Private Equity Fund Management, Pudong Science And Technology Innovation Investment Fund

## Investors

- China Everbright (https://capitalatlas.ai/funds/china-everbright) — Series A
- China International Capital Corporation (https://capitalatlas.ai/funds/china-international-capital-corporation) — Series A
- Cowin Capital (https://capitalatlas.ai/funds/cowin-capital) — Series A
- CASH Capital (https://capitalatlas.ai/funds/cash-capital) — Series A
- China Growth Capital (https://capitalatlas.ai/funds/china-growth-capital) — Series A
- Everest VC (https://capitalatlas.ai/funds/everest-vc) — Series A
- DYEE Capital (https://capitalatlas.ai/funds/dyee-capital) — Series A
- V Star Capital (https://capitalatlas.ai/funds/v-star-capital) — Series A
- Lanting Capital (https://capitalatlas.ai/funds/lanting-capital) — Series A
- Pudong Capital (https://capitalatlas.ai/funds/pudong-capital) — Series A
- Youshan Capital (https://capitalatlas.ai/funds/youshan-capital) — Series A
- Hangzhou Xiaochi Private Equity Fund Management (https://capitalatlas.ai/funds/hangzhou-xiaochi-private-equity-fund-management) — Series A
- Pudong Science And Technology Innovation Investment Fund — Series A
- Hanfu Capital (https://capitalatlas.ai/funds/hanfu-capital) — Series B
- Huajin Dadao Investment — Series B
- Mingzhe Asset (https://capitalatlas.ai/funds/mingzhe-asset) — Series B
- Shanghai Nuolin Pharmaceutical Partnership (Limited Partnership) — Series B
- Guangzhou Industry Investment Holding Group (https://capitalatlas.ai/funds/guangzhou-industry-investment-holding-group) — Series B